Revance Therapeutics, Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY®? (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults. DAXXIFY®?, powered by Peptide Exchange Technology??, was previously approved by the FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years.

Cervical dystonia is a chronic, debilitating disease in which the neck muscles contract invol voluntarily, causing abnormal movements, pain and awkward posture of the head and neck.12,13 Neuromodulators are considered the first line of treatment for this condition, which effects roughly 60,000 Americans. In 2017, the U.S. FDA grantedorphan drug designation to DAXXIFY®? for the treatment of cervical Dystonia in adults.

In 2017, the U.,S. FDA granted an drug designation to DAXXIFy®? for the treatment of spinal dystonia in adults.